| TABLE OF CONTENTS |
 |
 |
Editorial |
| |
By Vincenzo
Di Marzo, PhD
George Kunos, MD
|
page 3-6 |
| |
|
|
|
Pathogenesis of the metabolic syndrome and the influence of cannabinoids |
| |
By Richard N. Bergman, PhD |
pages 7-9 |
| |
|
|
|
Physiological and pathophysiological functions of the endocannabinoid system in the central nervous system |
| |
By Beat Lutz, PhD |
pages 10-13 |
| |
|
|
|
Peripheral functions of the endocannabinoid system: pathology and physiology |
| |
By Andreas Zimmer, PhD |
pages 14-17 |
| |
|
|
|
The endocannabinoid system and stress |
| |
By Cecilia J. Hillard, PhD |
pages 18-21 |
| |
|
|
|
Endocannabinoids and non-homeostatic controls of appetite |
| |
By Tim C. Kirkham, PhD |
pages 22-26 |
| |
|
|
|
The endocannabinoid system and the control of gastrointestinal function |
| |
By Keith A. Sharkey, PhD |
pages 27-30 |
| |
|
|
|
The endocannabinoid system in adipose tissue function |
| |
By Uberto Pagotto, MD, PhD |
pages 31-35 |
| |
|
|
|
The endocannabinoid system as a therapeutic target for liver diseases |
| |
By Sophie
Lotersztajn, PhD
Ariane Mallat, MD, PhD
|
pages 36-40 |
| |
|
|
|
The endocannabinoid system and cardiovascular disease |
| |
By Pal Pacher, MD, PhD, FAPS, FAHA |
pages 41-44 |
| |
|
|
|
Role of the endocannabinoid system in atherosclerosis |
| |
By François
Mach, MD
Fabrizio Montecucco, MD
Sabine Steffens, PhD
|
pages 45-46 |
| |
|
|
|
History of the development and clinical use of CB1 receptor inverse agonists/antagonists |
| |
By Gérard Le Fur, PhD |
pages 47-50 |
| |
|
|
|
Abdominal obesity, dyslipidemia, insulin resistance, type 2 diabetes and atherosclerosis: who is the right patient to be treated with CB1 receptor antagonists? |
| |
By Luc F. Van Gaal, MD, PhD
Jean-Pierre Després, PhD, FAHA |
pages 51-56 |
| |
|
|
| |
|
|
